GSK, Spero Stop UTI Drug Trial After Early Success

GSK, Spero stop UTI drug trial after early success

(Reuters) -Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract infections early as the study met its main goal, the companies said on Wednesday. Shares of Spero more than tripled to $2.24 in premarket trading. The decision comes after a recommendation from an independent committee that completed an interim analysis of data from 1,690 patients enrolled in the trial. The com…

GSK-licensed antibiotic meets goal in late-stage study

The British drugmaker may have succeeded in reviving an oral antibiotic previously rejected by the FDA when it was under development at Spero.

Genomics Reveal Staphylococcus aureus Persists during Long-term Urinary Catheterization Despite Antimicrobial Therapy and Catheter Exchanges

Urinary catheters, the most frequently placed medical devices in the US, increase the risk of developing symptomatic catheter-associated urinary tract infection (CAUTI) and asymptomatic bacteriuria (ASB) – the presence of bacteria in the urine – with those requiring long-term urina...

GSK & adesso expand DREAM digital reminders to 23 countries

GSK and adesso have expanded their DREAM digital reminder service for medication and vaccination adherence to 23 countries, enhancing global patient support.

GSK and Spero halt UTI antibiotic trial early due to high efficacy

GSK plans to submit an NDA for tebipenem HBr to the US Food and Drug Administration (FDA) by the end of 2025.The post GSK and Spero halt UTI antibiotic trial early due to high efficacy appeared first on Clinical Trials Arena.

Tebipenem HBr cUTI trial ends early after meeting efficacy goals

GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.